Yu Yong 4
4 · GENELUX Corp · Filed Sep 3, 2025
Insider Transaction Report
Form 4
GENELUX CorpGNLX
Yu Yong
VP, Clinical Trial Operations
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-09-01−207,652→ 0 totalExercise: $6.00Exp: 2029-09-20→ Common stock (207,652 underlying) - Award
Stock Option (Right to Buy)
2025-09-01+207,652→ 207,652 totalExercise: $3.33Exp: 2029-09-20→ Common stock (207,652 underlying) - Award
Stock Option (Right to Buy)
2025-09-01+65,000→ 65,000 totalExercise: $3.33Exp: 2033-09-10→ Common stock (65,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-09-01−65,000→ 0 totalExercise: $22.40Exp: 2033-09-10→ Common stock (65,000 underlying)
Footnotes (3)
- [F1]The shares subject to the option are fully vested.
- [F2]The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.
- [F3]The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.